caa a22 4500 475748565 CHVBK 20180406123520.0 cr unu---uuuuu 170329e20000301xx s 000 0 eng 10.1023/A:1006697728855 doi (NATIONALLICENCE)springer-10.1023/A:1006697728855 Autoimmune and Antitumor Consequences of Antibodies Against Antigens Shared by Normal and Malignant Tissues [Elektronische Daten] [Philip Livingston, Govindaswami Ragupathi, Cristina Musselli] There is now a considerable body of information documenting the autoimmune consequences of antibodies induced by growing malignancies, or by passively administered and actively induced antibodies, in cancer patients against antigens shared by normal and malignant tissues. This provides a rich source of information addressing the consequences of autoantibodies against a range of antigens. Antibodies against cell-surface or intracellular antigens in the central nervous system (CNS) or on epithelial surfaces of normal tissues do not generally result in autoimmunity, but the same types and titers of antibodies against cell surface antigens in the subepidermal skin, peripheral nerves, blood, or vascular sites such as the spleen and bone marrow readily induce autoimmunity. The blood brain barrier of the CNS and apical antigen expression and the basement membrane in epithelial tissues, may protect these sites from antibody induced damage. Cancer cells, however, are protected by neither unidirectional antigen expression nor basement membranes. Vaccine induced antibodies against a variety of cancer cell surface antigens have been associated with prevention of tumor recurrence in preclinical models and in vaccinated cancer patients, in the absence of demonstrable autoimmunity. This forms the basis for a series of ongoing Phase III trials with single or polyvalent antigen cancer vaccines designed for optimal antibody induction. Plenum Publishing Corporation, 2000 B cells nationallicence antigens nationallicence Livingston Philip Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut Ragupathi Govindaswami Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut Musselli Cristina Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut Journal of Clinical Immunology Kluwer Academic Publishers-Plenum Publishers 20/2(2000-03-01), 85-93 0271-9142 20:2<85 2000 20 10875 https://doi.org/10.1023/A:1006697728855 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1006697728855 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Livingston Philip Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut NATIONALLICENCE 700 1- Ragupathi Govindaswami Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut NATIONALLICENCE 700 1- Musselli Cristina Department of Medicine, Memorial Sloan-Kettering Cancer Center, 10021, New York, New York, USA aut NATIONALLICENCE 773 0- Journal of Clinical Immunology Kluwer Academic Publishers-Plenum Publishers 20/2(2000-03-01), 85-93 0271-9142 20:2<85 2000 20 10875 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer